TABLE 1.

Details of the studies

Study	No. of serum samples	Vaccine	Study parameters			Assay details		Location of results
			Country	Immunization schedulea	Age at sampling	ELISA	Laboratory
A	70	11-valent candidate PCV (GSK)	Germany	3, 4, 5 mo	6 mo	WHO non-22F	ICH	Fig. 1
			Lithuania	3, 4.5, 6 mo	7 mo	GSK 22F	GSK
			Argentina	2, 4, 6 mo	16-19 mo
				Boost at 15-18 mo
			Costa Rica	2, 4, 6 mo	13-16 mo
				Boost at 12-15 mo
B	140	Prevenar	Germany	2, 3, 4 mo	5 mo	GSK 22F	GSK	Fig. 2
	140	Meningitec	Germany	2, 3, 4 mo	5 mo
C	118	Prevenar	Germany	2, 3, 4 mo	5 mo	WHO non-22F	ICH	Fig. 3
						GSK 22F	GSK
						WHO 22F	ICH
D	78	Investigational nine-valent	South Africa	6, 10, 14 wk	17-20 wk	THL non-22F	THL	Fig. 4
		PCV (Wyeth)				THL 22F	THL
E	50	Prevenar	Poland	2, 4, 6 mo	5 mo	WHO non-22F	GSK	Fig. 5
						GSK 22F	GSK
	50	Synflorix	Poland	2, 4, 6 mo	5 mo
F	32	Nonvaccinated	Philippines		6 wk	WHO non-22Fb	GSK	Table 4
			Israel		2 mo	GSK 22Fb	GSK

^aAge of immunization.

^bATCC PS and GSK PS were compared in both assays.